NCT05363280 2025-09-23
Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC
Advenchen Laboratories, LLC
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT06737081 2024-12-17
SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT06092606 2023-10-23
A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
Monyan Pharmaceutical (Shanghai) Co., Ltd.
Phase 2 Unknown
NCT05352646 2023-09-28
NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection
Newish Technology (Beijing) Co., Ltd.
Phase 1 Unknown